MIRM8:05 AMMirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026mirumpharma.com
MIRM4:01 PMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)mirumpharma.com
MIRM11:56 PMMirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notesmirumpharma.com
MIRM4:01 PMMirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Updatemirumpharma.com
MIRM8:00 AMMirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing CholangitisTrial Resultsmirumpharma.com
MIRM5:00 PMMirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026Results CallCall Mon, May 4, 2026mirumpharma.com
MIRM4:01 PMMirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026mirumpharma.com
MIRM8:00 AMMirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta VirusTrial Results • Phase 2mirumpharma.com
MIRM4:01 PMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)mirumpharma.com
MIRM8:00 AMMirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver DiseasesEnrollment • Phase 3mirumpharma.com
MIRM5:30 PMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)mirumpharma.com
MIRM8:00 AMMirum Pharmaceuticals Completes AZURE-1 Enrollment and AZURE-4 Screening in Phase 3 Program of brelovitug in Chronic Hepatitis Delta VirusEnrollment • Phase 3mirumpharma.com